Cost-effectiveness of semaglutide 2.4 mg versus liraglutide 3 mg for the treatment of obesity in Greece
BackgroundObesity is a major public health issue associated with significant humanistic and economic burden. In Greece, liraglutide 3.0 mg is currently the only reimbursed pharmacotherapy for obesity, restricted to patients with morbid obesity and selected comorbidities. Semaglutide 2.4 mg has demon...
Wedi'i Gadw mewn:
| Prif Awduron: | , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Frontiers Media S.A.
2025-10-01
|
| Cyfres: | Frontiers in Public Health |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.frontiersin.org/articles/10.3389/fpubh.2025.1690211/full |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|